LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
Farzaneh Atashrazm,1 Nicolas Dzamko2 1Neuroscience Research Australia, Randwick; 2School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia Abstract: Major advances in understanding how genetics underlies Parkinson’s disease (PD) have provid...
Guardado en:
Autores principales: | Atashrazm F, Dzamko N |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f5632c429f854b89b5083f7a96af03fd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
TFEB Dependent Autophagy-Lysosomal Pathway: An Emerging Pharmacological Target in Sepsis
por: Xin Liu, et al.
Publicado: (2021) -
Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
por: Sahar M. El‑Haggar, et al.
Publicado: (2022) -
Intestinal Macrophage Autophagy and its Pharmacological Application in Inflammatory Bowel Disease
por: Yang Zheng, et al.
Publicado: (2021) -
The Secrets of Alternative Autophagy
por: Kaja Urbańska, et al.
Publicado: (2021) -
Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy
por: Yanan Li, et al.
Publicado: (2021)